Intelligent Bio Solutions Completes $3 Million Public Offering
Intelligent Bio Solutions Inc. (NASDAQ: INBS), a forward-thinking medical technology company, has recently finalized its public offering by closing on the sale of 1,500,000 shares of common stock. This strategic move was executed at a commendable price of $2.00 per share, which demonstrates the Company’s strong market positioning and appeal.
Details of the Offering
This offering included a full exercise of the underwriter’s option, allowing for an additional 195,652 shares to be purchased. As a result, the total gross proceeds from this offering are approximately $3.0 million, not accounting for underwriting discounts, commissions, or associated expenses.
Underwriter's Role
Ladenburg Thalmann & Co. Inc. played a vital role as the sole bookrunning manager for this public offering. Their expertise likely contributed to the successful execution and strong investor interest showcased throughout this process.
Regulatory Compliance and Transparency
The offering was conducted under a shelf registration statement filed with the Securities and Exchange Commission (SEC). This not only reflects compliance with regulatory standards but also highlights the Company’s commitment to transparency with investors.
Access to Documentation
For those interested in the specifics of the offering, a final prospectus supplement and related documents were duly filed with the SEC and can be directly accessed through their platform. Moreover, additional copies are available through the underwriter upon request.
About Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc. revolutionizes the medical technology space with its groundbreaking Intelligent Fingerprinting Drug Screening System. This innovative product makes use of fingerprint sweat analysis for drug testing, which allows for rapid and non-invasive results within minutes. Such capabilities hold significant value, especially for employers in industries where safety is paramount.
Applications of Their Technology
The Company’s testing solutions target various substances commonly found in workplace environments—such as opiates, cocaine, methamphetamine, and cannabis—which further underscores the broad applicability of their technology. Countries beyond the U.S. are actively exploring the adoption of their solutions in sectors like construction, manufacturing, logistics, and drug treatment.
Looking Ahead
As Intelligent Bio Solutions continues to develop its technology, the potential for expansion into new markets and applications remains significant. The Company is focused on enhancing its testing methodologies and capturing broader audience segments with innovative, accessible solutions.
Investor Relations and Company Contact
For inquiries or further information, individuals can reach out via email at info@ibs.inc. Intelligent Bio Solutions warmly encourages stakeholders, investors, and interested parties to stay connected through their social media channels on LinkedIn and Twitter.
Frequently Asked Questions
What is the recent achievement of Intelligent Bio Solutions?
The Company has successfully closed a public offering, raising approximately $3 million.
Who managed the public offering?
Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager for this public offering.
What are the major applications of their technology?
Intelligent Fingerprinting Drug Screening System is used for rapid, non-invasive drug testing, beneficial in safety-critical industries.
How does Intelligent Bio Solutions ensure transparency?
The Company complies with SEC regulations and provides access to necessary documentation for its offerings.
What sectors might utilize Intelligent Bio Solutions' testing solutions?
Their innovative testing solutions target sectors like construction, manufacturing, drug treatment, and logistics, among others.
